Multiple myeloma is an incurable malignancy mainly due to the emergence of drug resistance. Mechanistic studies have shown that the expression of MDR1/P-glycoprotein accounts for only a portion of the drug resistant phenotype. Another mechanism of drug resistance in this disease may be the inability of anticancer drugs to activate signaling pathways required for programmed cell death (PCD). The PCD pathways may be tissue or tumor specific, and anti-cancer drugs may be more effective at activating certain pathways compared to others. The Fas/Fas Ligand pathway serves primarily as a means to regulate the homeostasis of the immune system by eliminating chronically activated lymphocytes. If anti-cancer drugs initiate PCD in hematopoietic malignancies by utilizing components of the Fas-mediated apoptotic pathway, then an abnormality or blockade in this pathway could result in drug resistance. Conversely, if anti-cancer drugs select for an abnormality or mutation in the Fas pathway, then this could result in resistance to Fas-mediated apoptosis. The applicant will examine the signaling pathway for Fas-mediated apoptosis in myeloma cell lines and patient specimens to determine if a relationship exists between drug sensitivity and Fas-mediated apoptosis.
Specific Aims 1 and 2 will focus on the Fas receptor (Fas) and Fas ligand (FasL) by determining if loss of expression or presence of mutations in either of these molecules impairs Fas-mediated or drug induced apoptosis.
Specific Aim 3 will examine the role of IL-6 in preventing PCD mediated by Fas activation or drug exposure.
Specific Aim 4 will determine if drug treatment selects for Fas-mediated resistance in vivo. A fundamental understanding of Fas-mediated apoptosis, and mechanisms by which cells become resistant to this apoptotic pathway, may be critical to the understanding of how myeloma cells avoid immune surveillance and possibly become drug resistant.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA077859-01
Application #
2622637
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Johnson, George S
Project Start
1998-06-01
Project End
2001-04-30
Budget Start
1998-06-01
Budget End
1999-04-30
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of South Florida
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Tampa
State
FL
Country
United States
Zip Code
33612
Lin, J; Lwin, T; Zhao, J-J et al. (2011) Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia 25:145-52
Xiang, Yun; Remily-Wood, Elizabeth R; Oliveira, Vasco et al. (2011) Monitoring a nuclear factor-?B signature of drug resistance in multiple myeloma. Mol Cell Proteomics 10:M110.005520
Remily-Wood, Elizabeth R; Liu, Richard Z; Xiang, Yun et al. (2011) A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin Appl 5:383-96
Perez, Lia E; Parquet, Nancy; Meads, Mark et al. (2010) Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. Eur J Haematol 84:212-22
Lwin, Tint; Lin, Jianhong; Choi, Yong Sung et al. (2010) Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood 116:5228-36
Zhao, Jian-Jun; Lin, Jianhong; Lwin, Tint et al. (2010) microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 115:2630-9
Meads, Mark B; Li, Zhi-Wei; Dalton, William S (2010) A novel TNF receptor-associated factor 6 binding domain mediates NF-kappa B signaling by the common cytokine receptor beta subunit. J Immunol 185:1606-15
Shain, Kenneth H; Dalton, William S (2009) Environmental-mediated drug resistance: a target for multiple myeloma therapy. Expert Rev Hematol 2:649-62
Yarde, Danielle N; Oliveira, Vasco; Mathews, Linda et al. (2009) Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 69:9367-75
Shain, Kenneth H; Yarde, Danielle N; Meads, Mark B et al. (2009) Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 69:1009-15

Showing the most recent 10 out of 29 publications